Masimo sues U.S Customs over approval of Apple Watch imports

Medical monitoring firm Masimo has sued U.S. Customs and Border Protection (CBP) over its decision to allow Apple to import Apple Watches equipped with blood-oxygen reading technology. Masimo contends CBP improperly reversed its prior stance without justification or notification, effectively undermining a 2023 U.S. International Trade Commission (ITC) import ban Masimo secured against Apple for patent infringement. This legal action escalates the ongoing intellectual property dispute, challenging a federal agency's enforcement of trade rulings and aiming to reinstate the import block on Apple's blood-oxygen enabled devices.

Analysis

Masimo has escalated its intellectual property dispute with Apple by initiating legal action against a U.S. federal agency, the Customs and Border Protection (CBP). The lawsuit contends that the CBP improperly reversed a 2023 U.S. International Trade Commission (ITC) import ban on Apple Watches featuring blood-oxygen technology, which was found to infringe on Masimo's patents. This development represents a significant strategic setback for Masimo, as it effectively undermines the commercial leverage gained from its prior ITC victory. The strongly negative sentiment score for Masimo (-0.7) reflects investor concern that its primary enforcement mechanism has been circumvented, forcing it into a new and uncertain legal battle against a government body. Conversely, the mildly negative sentiment for Apple (-0.2) suggests the market views this as a resolution to a product feature gap, with the continued litigation being a manageable overhang. Apple's ability to resume imports of its Series 9 and Ultra 2 watches with the contested feature, based on the CBP's approval, mitigates a notable business risk and restores a key competitive differentiator.

Key Decisions for Investors

• Investors in Masimo should recognize the heightened risk profile, as the circumvention of the ITC exclusion order by the CBP introduces significant uncertainty regarding the company's ability to monetize and defend its intellectual property against Apple.
• For Apple investors, the CBP's decision is a tactical victory that reduces a near-term headwind for its wearables division, though the ongoing and expanding litigation with Masimo remains a persistent, low-level risk factor to monitor.
• Traders should closely watch the outcome of Masimo's lawsuit against the CBP, as a court ruling to halt the agency's decision could abruptly reimpose the import ban and reverse the current market advantage held by Apple.